retatrutide approval status 2025 HAS NOT BEEN APPROVED YET & CURRENTLY IN PHASE III CLINICAL TRIALS⛔️ Retatrutide is not currently FDA-approved, as it is in Phase III clinical trials with anticipated completion in 2025–2026 and June 8, 2026: Reckless physicians
Description
Nature 562:589594
While further research is needed to define the efficacy and safety of GLP-1RAs specifically in IBD, these agents are already widely prescribed for comorbid obesity and T2DM
The tirzepatide dosing schedule involves increases every four weeks, and each increase can temporarily worsen GI symptoms and electrolyte losses
For example, seven people (about 24 percent) on liraglutide reported worse mood, but so did eight (roughly 26 percent) on placebo
This is one of the main reasons people gain weight back after stopping GLP-1 therapy
